Telix Pharma (TLX) is held by 32 ASX ETFs. Over the last year it rose 4.9%: on $10,000, +$490. We explain 21 big moves in that time.
About TLX
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$5.4b
- Held by32 ETFs
- Big moves21 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −10.3%21 Sep 2026· Takeover / M&A
Telix Pharmaceuticals shares fell sharply after announcing a major US$1.65 billion acquisition of ITM Isotope Technologies, with investors reacting negatively to the scale and cost of the deal.
- +11.2%15 Sep 2026· Sector Flow
The ASX Health Care sector rose strongly on the same day, lifting TLX as part of a broad sector rotation into health stocks.
- −8.3%21 Aug 2026· Sector Flow
TLX fell sharply in sympathy with a broader US market sell-off and weakness in the Australian healthcare sector, with no company-specific news to explain the move.
- +8.0%24 Jun 2026· Analyst
Positive analyst commentary and sector flows into ASX healthcare names, with Telix highlighted as a recovering growth share, likely drove the move.
- −5.8%22 May 2026· Sector Flow
The stock drop was part of a broader selloff in ASX 200 shares, with Telix Pharmaceuticals among the biggest losers for the day.
- +7.7%14 Apr 2026· Contract
Telix Pharmaceuticals announced a radiopharma collaboration with Regeneron, a multi-billion dollar deal, driving the share price up 7.72%.
- +7.3%10 Apr 2026· Contract
Telix Pharmaceuticals shares rose on the announcement of a major radiopharma partnership with Regeneron, including a $40 million upfront payment.
- +5.9%18 Mar 2026· Analyst
Telix Pharmaceuticals shares continued to bounce off lows, likely driven by a positive analyst mention and biotech sector interest despite a recent FDA-related drop.
- +6.6%17 Mar 2026· Regulatory
Telix shares bounced off lows after a recent drop, despite a favorable US FDA update that was followed by buying interest.
- +7.8%10 Mar 2026· Operational
Positive Phase 3 trial results for Telix's prostate cancer therapy triggered the stock surge.
- −5.1%9 Mar 2026· Operational
Telix Pharmaceuticals shares fell 5.12% on March 8, 2026, ahead of the positive Phase 3 trial results announced on March 10, likely due to profit-taking or de-risking ahead of the binary readout.
- +6.5%6 Mar 2026· Contract
Telix's expansion of its AI-driven imaging push, highlighted in a research partnership announced on the event date, likely drove the stock up.
- +10.9%26 Feb 2026· Guidance Up
Telix Pharmaceuticals' shares surged following strong 2026 guidance, a shelf filing, and a TLX101-Px milestone, as reported in news articles around the date.
- −6.0%24 Feb 2026· Unknown
Despite positive news of 2026 guidance, a shelf filing, and a TLX101-Px milestone, the stock fell 6.04% on the event date.
- −7.9%23 Feb 2026· Sector Flow
Telix Pharmaceuticals shares fell after a significant rally on Friday following FY25 results, likely due to profit-taking and market digestion of the news.
- +14.2%20 Feb 2026· Earnings Beat
Telix Pharmaceuticals shares jumped 14.24% after reporting strong FY2025 results with 56% revenue growth and a positive FY2026 outlook.
- −6.9%12 Feb 2026· Sector Flow
Telix Pharmaceuticals fell amid a broad market downturn that pushed 13 ASX 200 stocks to multi-year lows, with no stock-specific adverse news.
- +8.3%27 Jan 2026· Sector Flow
Telix Pharmaceuticals shares bounced off multi-year lows amid broader ASX 200 market momentum and mention as a potentially undervalued stock, with no company-specific catalyst identified.
- −7.7%21 Jan 2026· Unknown
The stock fell sharply following a prior 55% sell-off, despite emerging China regulatory progress and positive full-year guidance updates.
- −6.6%17 Dec 2025· Regulatory
Telix Pharmaceuticals fell 6.61% on December 16, 2025, due to news of a potential US class action lawsuit over alleged disclosure failings, exacerbating an ongoing steep decline.
- +16.3%15 Oct 2025· Unknown
No direct news found; likely driven by positive sector sentiment in healthcare or a company-specific announcement not captured in the provided articles.
Held by 32 ETFs
Of every $10,000 in each fund, how much is in TLX today.
- MVEVanEck S&P/ASX MidCap ETF$1471.47%
- FAIRBetaShares Australian Sustainability Leaders ETF$920.92%
- VSOVanguard MSCI Australian Small Companies Index ETF$760.76%
- GRNVVanEck MSCI Australian Sustainable Equity ETF$620.62%
- OZXXGlobal X Australia ex Financials & Resources ETF$560.56%
- EX20BetaShares Australian Ex-20 Portfolio Diversifier ETF$470.47%
- GEARBetaShares Geared Australian Equities Complex ETF$380.38%
- VETHVanguard Ethically Conscious Australian Shares ETF$230.23%
- AYLDGlobal X S&P/ASX 200 Covered Call Complex ETF$180.18%
- STWSTATE STREET SPDR S&P/ASX 200 ETF$180.18%
Why did TLX fall 7.7% on 21 Jan 2026?
Telix Pharma
The stock fell sharply following a prior 55% sell-off, despite emerging China regulatory progress and positive full-year guidance updates.
The magnitude of the drop (-7.66%) and volume (4.25x) suggest a significant event, but the two main articles on the event date present conflicting narratives: one highlights China regulatory progress, the other an upgrade. The 'Inside Biotech' article from the next day mentions fragility, implying the sell-off momentum continued. However, no single clear categorical driver (e.g., earnings miss, regulatory action, analyst downgrade) is directly identified, leaving the cause uncertain.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
What it did to the 32 ETFs holding TLX
On $10,000 in each fund, at the weight it holds today
- MVE1.47% of the fund−$11
- FAIR0.92% of the fund−$7
- VSO0.76% of the fund−$6
- GRNV0.62% of the fund−$5
- OZXX0.56% of the fund−$4
- EX200.47% of the fund−$4
- GEAR0.38% of the fund−$3
- VETH0.23% of the fund−$2
- AYLD0.18% of the fund−$1
- STW0.18% of the fund−$1
The 10 that hold it most. All 32 are listed on the page under Held by.